Adult Dosing

Neutropenia associated with myelosupressive chemotherapy

• 6 mg SC once per chemotherapy cycle

• Do not give within 24 hr post chemotherapy or 14 days pre chemotherapy
• Do not administer the product in patient with latex allergies
• Do not administer the product if discoloration or particulates are observed in the solution/container

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Decreasing incidence of infection manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs

• Hypersensitivity to any of the ingredients of the product
• History of serious allergic reactions
• Hypersensitivity to E.coli proteins
• Not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Fatal splenic rupture have occurred on administration of pegfilgrastim, diagnose for enlarged spleen or splenic rupture in patients complaining for pain in left upper abdomen or shoulder
• Acute respiratory distress syndrome (ARDS) has occurred on administration. Discontinue the drug if patients develops fever, lung infiltrates or respiratory distress after administration
• Fatal allergic reactions, including anaphylaxis, have occurred on initial exposure of the drug and on discontinuation of initial anti-allergic treatment
• Discontinue therapy permanently on occurrence of fatal allergic reaction and avoid use in patient with history of fatal allergic reactions with pegfilgrastim or filgrastim
• On administration of drug, severe and life threatening sickle cell crises may occur in patients with sickle cell disorders
• Potentially acts as a tumor growth factor for myeloid malignancies and myelodysplasia
• Perform complete blood count and platelet count at baseline and then periodically

Cautions: Use cautiously in

• Sickle cell disease
• Myelodysplasia
• Myeloid malignancy

Pregnancy Category:C.

Breastfeeding: Safety Unknown, manufacture advises to use cautiously when administrating to nursing mothers

• GI: Splenic rupture, splenomegaly, elevated alkaline phosphotase, nausea, abdominal pain, flank pain
• RESP: ARDS
• HEMA: Sickle cell crisis, leukocytosis, thrombocytopenia, anemia
• CV: Angioedema, hypotension
• DERM: Injection site reaction, allergic reactions, anaphylaxis, Sweet’s syndrome, generalized erythema and flushing
• METABOLIC : Elevated LDH, hyperuricemia
• CNS: Headache
• MUSC: Medullary bone pain, musculoskeletal pain

• Colony-stimulating factor; acts on hematopoietic cells by binding to specific cell surface receptors, resulting in proliferation, differentiation, commitment and end cell functional activation
• Metabolism: Unknown
• Excretion: Unknown
• Half-Life: 15-80 hrs

US Trade Name(s)

• Neulasta

US Availability

Neulasta

• INJ (prefilled syringes): 6 mg/0.6mL

Canadian Trade Name(s)

• Neulasta

Canadian Availability

Neulasta

• INJ (prefilled syringes): 6 mg/0.6mL

UK Trade Name(s)

• Neulasta

UK Availability

Neulasta

• INJ (prefilled syringes): 6 mg/0.6mL

Australian Trade Name(s)

• Neulasta

Australian Availability

Neulasta

• INJ (prefilled syringes): 6 mg/0.6mL

[Outline]

Hematology/Oncology

Colony Stimulating Factors

Infectious Disease

Colony Stimulating Factors

Pricing data from www.DrugStore.com in U.S.A.

• Neulasta 6 MG/0.6ML SOLN [Syringe] (AMGEN)
  0.6 0.6ml = $3600.06
  1.2 0.6ml = $7099.74

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.